Abstract
The endocannabinoid system has been proposed to modulate a variety of physiological processes, including those that underlie cognition. The present study tested whether this system is tonically active in learning and memory by comparing CB1 receptor knockout mice (CB1−/−) to wild-type mice (CB1+/+) in several Morris water maze tasks. Also, the effects of three cannabinoid agonists, Δ9-tetrahydrocannabinol (Δ9-THC),R-(+)-[2,3-dihydro-5-methyl-3[morpholinyl)methyl]-pyrrolo[1,2,3-de]-1, 4-benzoxazinyl]-(1-naphthalenyl)methanone mesylate (WIN 55,212-2), and methanandamide, were evaluated in a working memory procedure. Both genotypes exhibited identical acquisition rates in a fixed platform procedure; however, the CB1−/− mice demonstrated significant deficits in a reversal task in which the location of the hidden platform was moved to the opposite side of the tank. This phenotype difference was most likely due to an increased perseverance of the CB1−/− mice in that they continued to return to the original platform location, despite being repeatedly shown the new platform location. In addition, Δ9-THC (ED50 = 1.3 mg/kg), WIN 55,212-2 (ED50 = 0.35 mg/kg), and methanandamide (ED50 = 3.2 mg/kg) disrupted the performance of CB1+/+ mice in the working memory task at doses that did not elicit motivational or sensorimotor impairment as assessed in a cued version of the task. Furthermore, doses of each drug that were maximally disruptive in CB1+/+ mice were ineffective in eitherN-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide HCl (SR 141716A)-treated CB1+/+ or CB1−/− mice. These results provide strong evidence that cannabinoids disrupt working memory through a CB1 receptor mechanism of action, and suggest that the endocannabinoid system may have a role in facilitating extinction and/or forgetting processes.
Footnotes
-
This work was supported by National Institutes of Health Grants DA-03672, DA-09789, DA-07027, and DA-06094 and the National Institute on Drug Abuse Center for Drug Abuse Research Small Grants Program.
- Abbreviations:
- CB
- cannabinoid
- 2-AG
- 2-arachidonoylglycerol
- SR 141716A
- N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide HCl
- Δ9-THC
- Δ9-tetrahydrocannabinol
- WIN 55,212-2
- R-(+)-[2,3-dihydro-5-methyl-3[morpholinyl)methyl]-pyrrolo[1,2,3-de]-1, 4-benzoxazinyl]-(1-naphthalenyl)methanone mesylate
- ANOVA
- analysis of variance
- CI
- confidence interval
- CP 55,940
- (1R,3R,4R)-3-[2-hydroxy-4-(1,1-dimethylheptyl)phenyl]-4-(3-hydroxypropyl)cyclohexan-1-ol
- HU-210
- (−)-7-OH-Δ-6-tetrahydrocannabinol-dimethylheptyl
- Received November 29, 2001.
- Accepted February 13, 2002.
- The American Society for Pharmacology and Experimental Therapeutics
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|